{
  "nctId": "NCT02984943",
  "briefTitle": "The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis",
  "officialTitle": "The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis: A Pilot Study",
  "protocolDocument": {
    "nctId": "NCT02984943",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-03-12",
    "uploadDate": "2020-01-28T19:27",
    "size": 1531828,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02984943/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 14,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-01-19",
    "completionDate": "2019-04-10",
    "primaryCompletionDate": "2019-04-10",
    "firstSubmitDate": "2016-11-15",
    "firstPostDate": "2016-12-07"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n1. Age â‰¥ 18\n2. Active duty or Department of Defense (DoD) beneficiary\n3. Diagnosed with rheumatoid arthritis meeting ACR/EULAR 2010 classification criteria and any one of the following:\n\n   1. Patient does not want to be on rheumatologic medications\n   2. Patient has contraindications to standard rheumatologic medications\n   3. Patient has failed treatment or an incomplete response with standard rheumatologic medications\n4. Women of childbearing age must have a negative pregnancy test and currently be on a reliable form of birth control\n\nExclusion Criteria:\n\n1. Severe depression\n2. Dementia, mental disability\n3. Claustrophobia\n4. Uncontrolled seizure disorder\n5. Uncontrolled asthma/severe chronic obstructive pulmonary disease (COPD) with partial pressure of carbon dioxide (pCO2) \\> 45 mmHg on arterial blood gas\n6. Grade 4 congestive heart failure\n7. Unstable angina\n8. Chronic/acute otitis media/sinusitis\n9. Major tympanic membrane trauma\n10. Severe kyphoscoliosis\n11. Prior chemotherapy with Bleomycin and evidence of deterioration in diffusion capacity of the lung for carbon monoxide (DLCO) after a single hyperbaric oxygen exposure\n12. History of renal insufficiency or glomerular filtration rate (GFR)\\< 30\n13. Women that are currently pregnant or breast feeding or intend on becoming pregnant while enrolled in the study",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Sleep Quality - Trouble Falling Asleep, 6 Weeks",
        "description": "The Pain Sleep Quality (PSQ)-3 questionnaire will be used to measure outcome. Participants will score the question \"How often have you had trouble falling asleep because of pain?\" by placing a slash (/) on a 10 cm line directly beneath the question. The line will have \"never\" and \"always\" at each end. A ruler will be used to determine were the slash falls. The value between, 0-10, that corresponds on the ruler with the slash will be documented. \"0\" is a better outcome, and \"10\" is a worse outcome. The value for each participant will be combined to obtain a median and inter-quartile range at 6 weeks",
        "timeFrame": "6 weeks"
      },
      {
        "measure": "Sleep Quality - Trouble Falling Asleep, 6 Months",
        "description": "The PSQ-3 questionnaire will be used to measure outcome. Participants will score the question \"How often have you had trouble falling asleep because of pain?\" by placing a slash (/) on a 10 cm line directly beneath the question. The line will have \"never\" and \"always\" at each end. A ruler will be used to determine were the slash falls. The value between, 0-10, that corresponds on the ruler with the slash will be documented. \"0\"is a better outcome, and \"10\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 months.",
        "timeFrame": "6 months"
      },
      {
        "measure": "Sleep Quality - Morning Pain, 6 Weeks",
        "description": "The PSQ-3 questionnaire will be used to measure outcome. Participants will score the question \"How often have you been awakened by pain during the morning?\" by placing a slash (/) on a 10 cm line directly beneath the question. The line will have \"never\" and \"always\" at each end. A ruler will be used to determine were the slash falls. The value between, 0-10, that corresponds on the ruler with the slash will be documented. \"0\"is a better outcome, and \"10\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 weeks",
        "timeFrame": "6 weeks"
      },
      {
        "measure": "Sleep Quality - Morning Pain, 6 Months",
        "description": "The PSQ-3 questionnaire will be used to measure outcome. Participants will score the question \"How often have you been awakened by pain during the morning?\" by placing a slash (/) on a 10 cm line directly beneath the question. The line will have \"never\" and \"always\" at each end. A ruler will be used to determine were the slash falls. The value between, 0-10, that corresponds on the ruler with the slash will be documented. \"0\"is a better outcome, and \"10\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "Sleep Quality - Night Pain, 6 Weeks",
        "description": "The PSQ-3 questionnaire will be used to measure outcome. Participants will score the question \"How often have you been awakened by pain during the night?\" by placing a slash (/) on a 10 cm line directly beneath the question. The line will have \"never\" and \"always\" at each end. A ruler will be used to determine were the slash falls. The value between, 0-10, that corresponds on the ruler with the slash will be documented. \"0\"is a better outcome, and \"10\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 weeks",
        "timeFrame": "6 weeks"
      },
      {
        "measure": "Sleep Quality - Night Pain, 6 Months",
        "description": "The PSQ-3 questionnaire will be used to measure outcome. Participants will score the question \"How often have you been awakened by pain during the night?\" by placing a slash (/) on a 10 cm line directly beneath the question. The line will have \"never\" and \"always\" at each end. A ruler will be used to determine were the slash falls. The value between, 0-10, that corresponds on the ruler with the slash will be documented. \"0\"is a better outcome, and \"10\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "DAS28 - Global Health (GH), 3 Months",
        "description": "DAS28 quantifies disease activity based on visual analogue scales (VAS) assessment of well-being rated on a scale of 0-100 mm.\"0\"is a better outcome, and \"100\" is a worse outcome. The value for each participant will be combined to obtain a median and inter-quartile range at 3 months",
        "timeFrame": "3 months"
      },
      {
        "measure": "DAS28 - Global Health (GH), 6 Months",
        "description": "DAS28 quantifies disease activity based on visual analogue scales (VAS) assessment of well-being rated on a scale of 0-100 mm. \"0\"is a better outcome, and \"100\" is a worse outcome. The value for each participant will be combined to obtain a median and inter-quartile range at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "DAS28 - C-reactive Protein (CRP), 3 Months",
        "description": "DAS28 quantifies disease activity based on a mathematical formula that computes four variables: number of swollen and tender joints (total number of joints assessed is 28), CRP (mg/L) and visual analogue scales (VAS) for patient global assessment of well-being (0-100 mm). \"0\"is a better outcome, and \"100\" is a worse outcome. The value for each participant will be combined to obtain a median and inter-quartile range at 3 months",
        "timeFrame": "3 months"
      },
      {
        "measure": "DAS28 - C-reactive Protein (CRP), 6 Months",
        "description": "DAS28 quantifies disease activity based on a mathematical formula that computes four variables: number of swollen and tender joints (total number of joints assessed is 28), CRP (mg/L) and visual analogue scales (VAS) for patient global assessment of wellbeing (0-100 mm). \"0\"is a better outcome, and \"100\" is a worse outcome. The value for each participant will be combined to obtain a median and inter-quartile range at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "DAS28 - Erythrocyte Sedimentation Rate (ESR), 3 Months",
        "description": "DAS28 quantifies disease activity based on a mathematical formula that computes four variables: number of swollen and tender joints (total number of joints assessed is 28), ESR (mm/h) and visual analogue scales (VAS) for patient global assessment of well-being (0-100 mm). \"0\"is a better outcome, and \"100\" is a worse outcome. The value for each participant will be combined to obtain a median and inter-quartile range at 3 months",
        "timeFrame": "3 months"
      },
      {
        "measure": "DAS28 - Erythrocyte Sedimentation Rate (ESR), 6 Months",
        "description": "DAS28 quantifies disease activity based on a mathematical formula that computes four variables: number of swollen and tender joints (total number of joints assessed is 28), ESR (mm/h) and visual analogue scales (VAS) for patient global assessment of well-being (0-100 mm). \"0\"is a better outcome, and \"100\" is a worse outcome. The value for each participant will be combined to obtain a median and inter-quartile range at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "RAPID 3 - Abilities, 6 Weeks",
        "description": "A questionnaire that assesses abilities on a scale of 0-10. \"0\"is a better outcome, and \"10\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 weeks.",
        "timeFrame": "6 weeks"
      },
      {
        "measure": "RAPID 3 - Abilities, 6 Months",
        "description": "A questionnaire that assesses abilities on a scale of 0-10. \"0\"is a better outcome, and \"10\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "RAPID 3 - Pain, 6 Weeks",
        "description": "A questionnaire that assesses pain on a scale of 0-10. \"0\"is a better outcome, and \"10\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 weeks",
        "timeFrame": "6 weeks"
      },
      {
        "measure": "RAPID 3 - Pain, 6 Months",
        "description": "A questionnaire that assesses pain on a scale of 0-10. \"0\"is a better outcome, and \"10\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "RAPID 3 - Illness/Health, 6 Weeks",
        "description": "A questionnaire that assesses illness/health on a scale of 0-10. \"0\"is a better outcome, and \"10\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 weeks",
        "timeFrame": "6 weeks"
      },
      {
        "measure": "RAPID 3 - Illness/Health, 6 Months",
        "description": "A questionnaire that assesses illness/health on a scale of 0-10. \"0\"is a better outcome, and \"10\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "RAPID 3 - Cumulative Scores, 6 Weeks",
        "description": "The combined abilities, pain and illness/health scores. Recorded as a number between 0-30. \"0\"is a better outcome, and \"30\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 weeks",
        "timeFrame": "6 weeks"
      },
      {
        "measure": "RAPID 3 - Cumulative Scores, 6 Months",
        "description": "The combined abilities, pain and illness/health scores. Recorded as a number between 0-30. \"0\"is a better outcome, and \"30\" is a worse outcome. The value for each participant will be combined to report a median and inter-quartile range at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "RAPID 3 - Weighed Scores, 6 Weeks",
        "description": "The cumulative score conversion (based on a table). Recorded as a number between 0-10. 0-1 is near remission, 1.3-2 is low severity, 2.3 -4 is moderate severity, and 4.3 - 10 is high severity. The value for each participant will be combined to report a median and inter-quartile range at 6 weeks",
        "timeFrame": "6 weeks"
      },
      {
        "measure": "RAPID 3 - Weighed Scores, 6 Months",
        "description": "The cumulative score conversion (based on a table). Recorded as a number between 0-10. 0-1 is near remission, 1.3-2 is low severity, 2.3 -4 is moderate severity, and 4.3 - 10 is high severity. The value for each participant will be combined to report a median and inter-quartile range at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "VAS Pain Scale - 6 Weeks",
        "description": "A pain assessment using a horizontal line with numbers, 0-10, along the axis with endpoints \"no pain\" to \"worse possible pain\". \"0\"is a better outcome, and \"10\" is a worse outcome. Participants will mark on the line the level of pain they are experiencing now. The value for each participant will be combined to report a median and inter-quartile range at 6 weeks",
        "timeFrame": "6 weeks"
      },
      {
        "measure": "VAS Pain Scale - 6 Months",
        "description": "A pain assessment using a horizontal line with numbers, 0-10, along the axis with endpoints \"no pain\" to \"worse possible pain\". \"0\"is a better outcome, and \"10\" is a worse outcome. Participants will mark on the line the level of pain they are experiencing now. The value for each participant will be combined to report a median and inter-quartile range at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "MRI - Synovitis, Combined Score (CS), Right, 3 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-3 based on the proportion of bone involved. \"0\" is best outcome, \"3\"worse outcome. The median score of all 23 joints at baseline and 3 months will then be calculated for each participant. Participants with a lower median score at 3 months relative to baseline will be considered \"improved\" for the 3 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 3 months",
        "timeFrame": "3 months"
      },
      {
        "measure": "MRI - Synovitis, Combined Score (CS), Right, 6 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-3 based on the proportion of bone involved. \"0\" is best outcome, \"3\"worse outcome. The median score of all 23 joints at baseline and 6 months will then be calculated for each participant. Participants with a lower median score at 6 months relative to baseline will be considered \"improved\" for the 6 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "MRI - Synovitis, Combined Score (CS), Left, 3 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-3 based on the proportion of bone involved. \"0\" is best outcome, \"3\"worse outcome. The median score of all 23 joints at baseline and 3 months will then be calculated for each participant. Participants with a lower median score at 3 months relative to baseline will be considered \"improved\" for the 3 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 3 months",
        "timeFrame": "3 months"
      },
      {
        "measure": "MRI - Synovitis, Combined Score (CS), Left, 6 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-3 based on the proportion of bone involved. \"0\" is best outcome, \"3\"worse outcome. The median score of all 23 joints at baseline and 6 months will then be calculated for each participant. Participants with a lower median score at 6 months relative to baseline will be considered \"improved\" for the 6 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "MRI - Bone Erosion, Combined Score (CS), Right, 3 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-10 based on the proportion of bone involved. \"0\" is best outcome, \"10\"worse outcome. The median score of all 23 joints at baseline and 3 months will then be calculated for each participant. Participants with a higher median score at 3 months relative to baseline will be considered \"improved\" for the 3 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 3 months",
        "timeFrame": "3 months"
      },
      {
        "measure": "MRI - Bone Erosion, Combined Score (CS), Right, 6 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-10 based on the proportion of bone involved. \"0\" is best outcome, \"10\"worse outcome. The median score of all 23 joints at baseline and 6 months will then be calculated for each participant. Participants with a higher median score at 6 months relative to baseline will be considered \"improved\" for the 6 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "MRI - Bone Erosion, Combined Score (CS), Left, 3 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-10 based on the proportion of bone involved. \"0\" is best outcome, \"10\"worse outcome. The median score of all 23 joints at baseline and 3 months will then be calculated for each participant. Participants with a higher median score at 3 months relative to baseline will be considered \"improved\" for the 3 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 3 months",
        "timeFrame": "3 months"
      },
      {
        "measure": "MRI - Bone Erosion, Combined Score (CS), Left, 6 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-10 based on the proportion of bone involved. \"0\" is best outcome, \"10\"worse outcome. The median score of all 23 joints at baseline and 6 months will then be calculated for each participant. Participants with a higher median score at 6 months relative to baseline will be considered \"improved\" for the 6 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "MRI - Oedema, Combined Score (CS), Left, 3 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-3 based on the proportion of bone involved. \"0\" is best outcome, \"3\"worse outcome. The median score of all 23 joints at baseline and 3 months will then be calculated for each participant. Participants with a lower median score at 3 months relative to baseline will be considered \"improved\" for the 3 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 3 months",
        "timeFrame": "3 months"
      },
      {
        "measure": "MRI - Oedema, Combined Score (CS), Left, 6 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-3 based on the proportion of bone involved. \"0\" is best outcome, \"3\"worse outcome. The median score of all 23 joints at baseline and 6 months will then be calculated for each participant. Participants with a lower median score at 6 months relative to baseline will be considered \"improved\" for the 6 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "MRI - Oedema, Combined Score (CS), Right, 3 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-3 based on the proportion of bone involved. \"0\" is best outcome, \"3\"worse outcome. The median score of all 23 joints at baseline and 3 months will then be calculated for each participant. Participants with a lower median score at 3 months relative to baseline will be considered \"improved\" for the 3 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 3 months",
        "timeFrame": "3 months"
      },
      {
        "measure": "MRI - Oedema, Combined Score (CS), Right, 6 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-3 based on the proportion of bone involved. \"0\" is best outcome, \"3\"worse outcome. The median score of all 23 joints at baseline and 6 months will then be calculated for each participant. Participants with a lower median score at 6 months relative to baseline will be considered \"improved\" for the 6 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "Ultrasound - Synovitis, Combined Score (CS), Right, 3 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-3 based on the proportion of bone involved. \"0\" is best outcome, \"3\"worse outcome. The median score of all 23 joints at baseline and 3 months will then be calculated for each participant. Participants with a lower median score at 3 months relative to baseline will be considered \"improved\" for the 3 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 3 months",
        "timeFrame": "3 months"
      },
      {
        "measure": "Ultrasound - Synovitis, Combined Scale (CS), Right - 6 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-3 based on the proportion of bone involved. \"0\" is best outcome, \"3\"worse outcome. The median score of all 23 joints at baseline and 6 months will then be calculated for each participant. Participants with a lower median score at 6 months relative to baseline will be considered \"improved\" for the 6 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 6 months",
        "timeFrame": "6 months"
      },
      {
        "measure": "Ultrasound - Synovitis, Combined Score (CS), Left, 3 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-3 based on the proportion of bone involved. \"0\" is best outcome, \"3\"worse outcome. The median score of all 23 joints at baseline and 3 months will then be calculated for each participant. Participants with a lower median score at 3 months relative to baseline will be considered \"improved\" for the 3 month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at 3 months",
        "timeFrame": "3 months"
      },
      {
        "measure": "Ultrasound - Synovitis, Combined Score (CS), Left, 6 Months",
        "description": "Each of the 23 joints in the hand/wrist will be assigned a score from 0-3 based on the proportion of bone involved. \"0\" is best outcome, \"3\"worse outcome. The median score of all 23 joints at baseline and 6 months will then be calculated for each participant. Participants with a lower median score at 6 months relative to baseline will be considered \"improved\" for the t month time point. The number of participants with \"improved\" scores will be added to form the total number with improvement at t months",
        "timeFrame": "6 months"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 40,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 40
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:59.451Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}